GW Pharmaceuticals PLC- (GWPH) Stock Price Up 5.9%

GW Pharmaceuticals PLC- (NASDAQ:GWPH) rose 5.9% on Tuesday . The company traded as high as $151.71 and last traded at $149.20. Approximately 712,188 shares were traded during trading, an increase of 85% from the average daily volume of 385,364 shares. The stock had previously closed at $140.94.

GWPH has been the subject of a number of analyst reports. Cantor Fitzgerald set a $235.00 price objective on GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research note on Thursday, July 12th. BidaskClub cut GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. Zacks Investment Research cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Stifel Nicolaus initiated coverage on GW Pharmaceuticals PLC- in a research note on Tuesday, August 14th. They set a “buy” rating and a $181.00 price objective for the company. Finally, ValuEngine cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $181.38.

The company has a quick ratio of 8.21, a current ratio of 8.67 and a debt-to-equity ratio of 0.01. The company has a market cap of $4.14 billion, a P/E ratio of -22.11 and a beta of 2.75.



GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. The company had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $2.00 million. analysts expect that GW Pharmaceuticals PLC- will post -9.11 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in GWPH. WealthTrust Fairport LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the first quarter valued at about $104,000. Stratos Wealth Partners LTD. increased its holdings in shares of GW Pharmaceuticals PLC- by 216.0% in the first quarter. Stratos Wealth Partners LTD. now owns 948 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 648 shares during the period. Flagship Harbor Advisors LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the second quarter valued at about $109,000. Envestnet Asset Management Inc. acquired a new position in shares of GW Pharmaceuticals PLC- in the second quarter valued at about $119,000. Finally, Cowen Prime Services LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 708.0% in the second quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 885 shares during the period. 75.44% of the stock is currently owned by institutional investors and hedge funds.

About GW Pharmaceuticals PLC- (NASDAQ:GWPH)

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply